ClinicalTrials.Veeva

Menu

A Study of BL-M08D1 in Patients With Relapsed or Refractory Lymphoid Malignancies

S

Sichuan Baili Pharmaceutical

Status and phase

Enrolling
Phase 1

Conditions

Relapsed or Refractory Lymphoid Malignancies

Treatments

Drug: BL-M08D1

Study type

Interventional

Funder types

Industry

Identifiers

NCT06718634
BL-M08D1-102

Details and patient eligibility

About

This study is an open-label, multicenter, dose-escalation and extended-enrollment, nonrandomized phase I study to evaluate the safety, tolerability, pharmacokinetic characteristics and preliminary efficacy of BL-M08D1 for injection in relapsed or refractory lymphoid malignancies.

Enrollment

22 estimated patients

Sex

All

Ages

18 to 75 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  1. Sign the informed consent form voluntarily and follow the protocol requirements;
  2. Gender is not limited;
  3. Age: ≥18 years old and ≤75 years old;
  4. Expected survival time ≥3 months;
  5. Recurrent or refractory lymphoid malignancies confirmed by histopathology and/or cytology that are incurable or for which no standard treatment is currently available;
  6. Consent to provide archival tumor tissue samples or fresh tissue samples from primary or metastatic lesions within 2 years;
  7. ECOG≤2;
  8. The toxicity of previous antineoplastic therapy has returned to ≤ grade 1 as defined by NCI-CTCAE v5.0;
  9. No severe cardiac dysfunction, left ventricular ejection fraction ≥50%;
  10. Organ function level must meet the requirements;
  11. Coagulation function: international normalized ratio (INR) ≤1.5, and activated partial thromboplastin time (APTT) ≤1.5ULN;
  12. Urinary protein ≤2+ or ≤1000mg/24h;
  13. For premenopausal women of childbearing potential, a pregnancy test must be performed within 7 days before the initiation of treatment, serum pregnancy must be negative, and the patient must not be lactating; All enrolled patients (regardless of male or female) should use adequate barrier contraception during the whole treatment cycle and for 6 months after the end of treatment;
  14. Subjects were able and willing to comply with protocol-specified visits, treatment plans, laboratory tests, and other study-related procedures.

Exclusion criteria

  1. Chemotherapy, biological therapy and other anti-tumor therapies have been used within 4 weeks or 5 half-lives before the first dose; Palliative radiotherapy or traditional Chinese medicine with anti-tumor indications within 2 weeks before the first dose;
  2. History of severe heart disease;
  3. QT prolongation, complete left bundle branch block, III degree atrioventricular block;
  4. Active autoimmune and inflammatory diseases;
  5. Other malignant tumors diagnosed within 5 years before the first dose;
  6. Hypertension poorly controlled by two antihypertensive drugs (systolic blood pressure > 150 mmHg or diastolic blood pressure > 100 mmHg);
  7. Patients with poor glycemic control or with diabetic gangrene;
  8. A history of ILD requiring steroid therapy or current ILD or grade ≥2 radiation pneumonitis;
  9. Complicated with pulmonary diseases leading to clinically severe respiratory function impairment;
  10. Patients with central nervous system involvement;
  11. Had a history of or central nervous system disease;
  12. Patients with a history of allergy to recombinant humanized antibody or human-mouse chimeric antibody or to any component of BL-M08D1 excipients;
  13. Received previous organ transplantation or allogeneic hematopoietic stem cell transplantation (Allo-HSCT);
  14. Human immunodeficiency virus antibody positive, active tuberculosis, active hepatitis B virus infection or active hepatitis C virus infection;
  15. Active infection requiring systemic therapy within 4 weeks before the first dose of study drug;
  16. Pleural, abdominal, pelvic or pericardial effusion requiring drainage and/or with symptoms within 4 weeks before the first dose of study drug;
  17. Received another trial drug 4 weeks or 5 half-lives before the first dose;
  18. Pregnant or lactating women;
  19. Other conditions for participation in the trial were not considered appropriate by the investigator.

Trial design

Primary purpose

Treatment

Allocation

N/A

Interventional model

Single Group Assignment

Masking

None (Open label)

22 participants in 1 patient group

BL-M08D1
Experimental group
Description:
Participants receive BL-M08D1 as intravenous infusion for the first cycle (3 weeks). Participants with clinical benefit could receive additional treatment for more cycles. The administration will be terminated because of disease progression or intolerable toxicity occurring or other reasons.
Treatment:
Drug: BL-M08D1

Trial contacts and locations

1

Loading...

Central trial contact

Sa Xiao, PHD

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2025 Veeva Systems